Study to Evaluate the Efficacy of Uproleselan in Combination With Chemotherapy in Chinese Patients With R/R AML
Trial details
- Registry ID
- NCT05054543
- Phase
- Phase 3
Drug identity checked against registry records
Also recorded as GMI-1271
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Study to Evaluate the Efficacy of Uproleselan in Combination With Chemotherapy in Chinese Patients With R/R AMLNCT05054543 | APLM | Phase 3 | Terminated | 2024-08-22Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |